Measured by its ability to neutralize IL-9-induced proliferation in the MO7e human megakaryocytic leukemic cell line. Avanzi, G. et al. (1988) Br. J. Haematol. 69:359. The Neutralization Dose (ND50) is typically 1-5 μg/mL in the presence of 2 ng/mL Recombinant Human IL-9.
Please Note: Optimal dilutions should be determined by each laboratory for each application.
are available in the Technical Information section on our website.
Cell Proliferation Induced by IL-9 and Neutralization by Human IL-9 Antibody.
Recombinant Human IL-9 (Catalog # 209-IL) stimulates proliferation in the MO7e human megakaryocytic leukemic cell line in a dose-dependent manner (orange line), as measured by Resazurin (Catalog # AR002). Proliferation elicited by Recombinant Human IL-9 (2 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human IL-9 Monoclonal Antibody (Catalog # MAB2092). The ND50 is typically 1-5 μg/mL
Preparation and Storage
Reconstitute at 0.5 mg/mL in sterile PBS.
Reconstitution Buffer Available
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Human IL-9 was originally identified as a cytokine found in the conditioned medium of a human T cell leukemia virus type I (HTLV-I) transformed T cell line that is mitogenic for the factor-dependent human megakaryoblastic leukemic cell line, M07e. The cDNA encoding this cytokine was subsequently isolated by functional expression cloning and found to be similar to the mouse T cell growth factor III/P40. This human cytokine and its murine homologue are now designated as human and mouse IL-9. Besides HTLV-I or -II transformed T cell lines, rhIL-9 is also produced by activated human PBLs. Human IL-9 was also reported to be expressed by primary and cultured Hodgkin and Reed-Sternberg (H-RS) cells derived from Hodgkin’s disease patients, suggesting a possible role for rhIL-9 in the development of the pathophysiology of Hodgkin’s disease.
Human and murine IL-9 are also capable of enhancing in vitro survival of human T cell lines as well as synergizing with Epo to support erythroid colony formation in vitro. However, the mast cell enhancing activity associated with rmIL-9 has not yet been demonstrated in the human system and no human IL-9-dependent T cell clones have been identified.
The gene for rhIL-9 has been mapped to human chromosome 5. As in the mouse system, the human IL-9 cDNA encodes a 144 amino acid residue precursor protein with an 18 amino acid signal peptide that is cleaved to form the mature cysteine-rich protein with a predicted molecular mass of 14 kDa. Human IL-9 contains four potential N-linked glycosylation sites and the native rhIL-9 is a highly glycosylated protein. Human and mouse IL-9 share 56% and 67% homology at the amino acid and nucleotide levels, respectively. Although murine IL-9 is active on human cells, human IL-9 is not active on mouse cells.
Entrez Gene IDs:
3578 (Human); 16198 (Mouse)
Cytokine P40; HP40; IL9; IL-9; IL-9homolog of mouse T cell and mast cell growth factor 40; interleukin 9; interleukin-9; p40 cytokine; p40 T-cell and mast cell growth factor; P40; T-cell growth factor P40
Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.